Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 537 for:    "Skin cancer"

TLR4 Polymorphisms and Risk of Skin Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03122366
Recruitment Status : Active, not recruiting
First Posted : April 20, 2017
Last Update Posted : November 2, 2018
Sponsor:
Information provided by (Responsible Party):
Nabiha Yusuf, University of Alabama at Birmingham

Brief Summary:
Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene. Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer.

Condition or disease Intervention/treatment
Skin Cancer Diagnostic Test: Detection of single nucleotide polymorphisms (SNP)

Layout table for study information
Study Type : Observational
Actual Enrollment : 392 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: TLR4 Polymorphisms and Predisposition for Skin Cancer Development
Actual Study Start Date : February 2, 2009
Actual Primary Completion Date : September 27, 2011
Estimated Study Completion Date : September 27, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Skin Cancer


Intervention Details:
  • Diagnostic Test: Detection of single nucleotide polymorphisms (SNP)
    Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood


Primary Outcome Measures :
  1. single nucleotide polymorphism [ Time Frame: once during the course of study ]
    TLR4 SNP Asp299Gly



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
400 patients age 50 and older (case group) will be enrolled at the time of presentation for skin cancer excision surgery. These patients will be stratified into melanoma and non-melanoma skin cancer subgroups, and the non-melanoma subgroup will be further divided into prior and no prior history of skin cancer. All groups will have blood drawn at the time of enrollment. 400 patients age 50 and older (control group) with no personal history of skin cancer will be enrolled at our clinical trials unit. These patients will be stratified into family history and no family history of skin cancer subgroups, and will have blood drawn at the time of enrollment.
Criteria

Inclusion Criteria:

  • Male or female over the age of 50
  • Fitzpatrick skin type I-IV

Exclusion Criteria:

  • Tumor types other than basal cell carcinoma, squamous cell carcinoma and melanoma
  • Chronic immunosuppression due to transplant antirejection regimen or HIV/AIDS
  • Nevoid basal cell carcinoma syndrome, Cowden's syndrome, xeroderma pigmentosum or other syndrome with skin-cancer predisposition
  • Known exposure to arsenic or ionizing radiation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03122366


Locations
Layout table for location information
United States, Alabama
The Kirklin Clinic
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham

Layout table for additonal information
Responsible Party: Nabiha Yusuf, Associate Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT03122366     History of Changes
Other Study ID Numbers: F080815001
First Posted: April 20, 2017    Key Record Dates
Last Update Posted: November 2, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nabiha Yusuf, University of Alabama at Birmingham:
single nucleotide polymorphisms
Toll-like receptor-4

Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases